ARWR Arrowhead Pharmaceuticals, Inc.: שווי עסקי להכנסות

לוגו של חברה ציבורית arrowheadpharma.com (ARWR)

Arrowhead Pharmaceuticals (ARWR) capitalization depends on the results of RNA therapy clinical trials and the rate of cash burn. The EV/Sales ratio demonstrates the market valuation of the business accounting for debt load, and the current value of 14148.66 captures the real-time level. Stable demand for liver disease treatments ensures sales resilience, while the company's environmental profile is limited to standard laboratory waste control.

Arrowhead Pharmaceuticals (ARWR): שווי חברה להכנסות מ-23.11.2025 עד 20.11.2026

arrowheadpharma.com - פילוחים אנליטיים ומדדי מפתח (ARWR)

- מחיר נוכחי ושווי מניות חזוי:
הערכת שווי פונדמנטלית של החברה:ARWR - Arrowhead Pharmaceuticals
דוגמת מוצר של Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals' specialization in innovative RNA therapeutics drives a high intellectual capital valuation, which the market tracks via the EV/Sales trajectory to exclude the impact of debt load. This ratio compares the total enterprise value to sales volume, allowing investors to assess the premium paid for future growth and capture the rate of market value correction amid inflationary pressures.